Type 2 diabetes is not an event that happens suddenly. It is the clinical threshold, defined by a fasting glucose above 7.0 mmol/L or HbA1c above 48 mmol/mol, that arbitrary measurement conventions place on a continuous biological deterioration that began years or even decades earlier. The trajectory from metabolically healthy to frankly diabetic passes through years of progressive insulin resistance, during which the pancreas compensates by producing ever-increasing amounts of insulin to maintain normal blood glucose. Normal fasting glucose during this compensatory period does not mean metabolic health; it means the pancreas is working harder than it should have to. By the time fasting glucose rises above the pre-diabetes threshold, meaningful damage has already occurred to the vascular endothelium, the kidneys, and the cardiovascular system. The time to intervene is not when the damage is visible; it is before the damage begins.
How Insulin Resistance Develops Long Before Diabetes
Insulin resistance develops when the normal signalling pathway by which insulin stimulates glucose uptake into cells is disrupted. The insulin molecule binds to its receptor on the cell surface, triggering a phosphorylation cascade that causes GLUT4 transporters to move to the cell membrane and allow glucose entry. In insulin-resistant cells, this signalling cascade is impaired at multiple points, most commonly through excess intracellular lipid accumulation in skeletal muscle and liver cells, which disrupts the insulin receptor substrate phosphorylation required for downstream signalling. The result is that normal insulin concentrations fail to produce normal glucose uptake, and the pancreas compensates by producing more insulin to achieve the same effect.
The drivers of this intracellular lipid accumulation are excess caloric intake, particularly from refined carbohydrates and fructose that drive de novo lipogenesis in the liver; inadequate skeletal muscle mass, which reduces the total capacity for glucose disposal; sedentary behaviour, which reduces contraction-stimulated GLUT4 translocation that normally provides insulin-independent glucose uptake; and poor sleep, which increases cortisol and growth hormone patterns that impair insulin sensitivity. These are all modifiable factors, and the insulin resistance they produce is reversible in the early stages, before beta cell damage from chronic hyperinsulinaemia begins to reduce insulin secretory capacity.
The Biomarkers That Reveal Insulin Resistance Before Fasting Glucose Changes
Fasting insulin is the earliest and most accessible biomarker of insulin resistance. A fasting insulin of greater than 10 microU/mL in the presence of normal fasting glucose indicates that the pancreas is producing excess insulin to maintain glucose in the normal range, by definition indicating insulin resistance. HOMA-IR, calculated as fasting glucose in mmol/L multiplied by fasting insulin in microU/mL, divided by 22.5, provides a validated quantitative index of insulin resistance, with values above 1.5 to 2.0 generally considered insulin resistant in research populations, though some frameworks use higher thresholds. The test requires a standard fasting blood draw that adds approximately 30 seconds of laboratory processing time to a standard blood panel.
The triglyceride-to-HDL ratio provides an inexpensive metabolic health proxy available from the standard cholesterol panel. Research has found that a triglyceride-to-HDL ratio above 1.5 (using mmol/L values, approximately equivalent to 3.5 using mg/dL values used in some guidelines) is a reliable predictor of insulin resistance and atherogenic dyslipidaemia, correlating well with more detailed measures including HOMA-IR and ApoB. Waist circumference, measured at the umbilical level, provides a simple anthropometric surrogate for visceral fat accumulation: in UK populations, values above 94 cm in men and 80 cm in women indicate elevated metabolic risk from visceral adiposity, with values above 102 cm in men and 88 cm in women indicating substantially elevated risk.
Why Catching Insulin Resistance Before Diagnosis Matters for Reversal
The reversibility of metabolic dysfunction is strongly dependent on the stage at which it is identified. Early insulin resistance, characterised by elevated fasting insulin with normal fasting glucose and no beta cell damage, is highly responsive to lifestyle intervention. A well-designed programme combining caloric restriction or carbohydrate reduction, regular resistance exercise to rebuild muscle mass, improved sleep, and stress management can normalise insulin sensitivity in a matter of weeks to months at this stage, with no requirement for pharmacological intervention. The reversal evidence is unambiguous: the Diabetes Prevention Programme, the UK DiRECT trial, and multiple other large studies demonstrate that intensive lifestyle intervention can prevent progression from pre-diabetes to diabetes in the majority of those who implement it.
At the stage of established pre-diabetes, defined by fasting glucose between 5.6 and 6.9 mmol/L or HbA1c between 39 and 47 mmol/mol, reversal is still achievable but requires more intensive intervention and results are less complete in a proportion of patients. At the stage of frank type 2 diabetes, reversal to non-diabetic glycaemia is achievable in some patients with very intensive intervention including significant weight loss, as demonstrated by the DiRECT trial, but a proportion have progressed to sufficient beta cell loss that insulin secretion is permanently reduced and pharmacological management becomes indefinitely necessary. The window for prevention is longest and the effort required is least at the earliest stage of insulin resistance, before any diagnostic threshold has been crossed.
The Longevity MOT Metabolic Assessment at Zhen Wellness
The Longevity MOT metabolic health assessment at Zhen Wellness on the Isle of Man goes beyond the standard HbA1c or fasting glucose to include fasting insulin, HOMA-IR, triglycerides and the triglyceride-to-HDL ratio, uric acid, and waist circumference, providing a comprehensive picture of metabolic health that identifies insulin resistance at the earliest detectable stage. Where the assessment identifies significant insulin resistance, the personalised programme that follows addresses all four primary modifiable drivers: dietary quality and carbohydrate quantity, exercise with specific emphasis on resistance training and cardiovascular fitness, sleep optimisation, and stress management.
For adults on the Isle of Man who have a family history of type 2 diabetes, who carry significant abdominal fat, who are experiencing unexplained fatigue, weight gain despite normal calorie intake, skin tags, or other signs of insulin resistance, the Longevity MOT metabolic assessment provides the specific biological data needed to understand what is actually happening and what to do about it. Acting on this information at 45 rather than waiting for a type 2 diabetes diagnosis at 55 potentially avoids a decade of progressive vascular damage, all the downstream complications that accumulate over that decade, and the lifelong medication management that follows.
- Insulin resistance begins a decade or more before type 2 diabetes; fasting glucose remains normal while damage accumulates
- Fasting insulin above 10 microU/mL with normal glucose confirms compensatory hyperinsulinaemia and insulin resistance
- HOMA-IR above 1.5-2.0 quantifies insulin resistance from a standard fasting blood sample
- Triglyceride-to-HDL ratio above 1.5 (mmol/L) is a reliable insulin resistance proxy from standard cholesterol panels
- Waist circumference above 94 cm (men) or 80 cm (women) indicates elevated metabolic risk from visceral adiposity
- Early insulin resistance is highly reversible through lifestyle; reversal becomes harder and less complete at each successive stage
- The Diabetes Prevention Programme confirms lifestyle intervention prevents progression to diabetes in the majority of pre-diabetics
Sources
- Knowler, W.C., et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403.
- Lean, M.E.J., et al. (2018). Primary care-led weight management for remission of type 2 diabetes: the DiRECT open-label cluster-randomised trial. Lancet, 391(10120), 541-551.
- DeFronzo, R.A., & Tripathy, D. (2009). Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care, 32(Suppl 2), S157-S163.
- Srikanthan, P., & Karlamangla, A.S. (2011). Relative muscle mass is inversely associated with insulin resistance and prediabetes. Journal of Clinical Endocrinology and Metabolism, 96(9), 2898-2903.
- Ford, E.S., et al. (2010). Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer. Archives of Internal Medicine, 170(15), 1355-1362.